MarketCap
Facebook
X
TelegramQuartalsbericht 2025-Q2
hinzugefügt 13.08.2025
DURECT Corporation Betriebsaufwand 2011-2025 | DRRX
Betriebsaufwand Jährlich DURECT Corporation
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 44.6 M | 37.9 M | 44.8 M | 41.1 M | 35.9 M | 34.7 M | 31.7 M | 32.4 M | 47.6 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 47.6 M | 31.7 M | 39 M |
Betriebsaufwand anderer Aktien in der Arzneimittelhersteller
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
Canopy Growth Corporation
CGC
|
197 M | $ 1.74 | - | $ 187 M |  Canada |
 |
Alimera Sciences
ALIM
|
71.8 M | - | - | $ 142 M |  USA |
 |
Assertio Holdings
ASRT
|
133 M | $ 0.76 | - | $ 54 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
213 M | - | - | $ 754 M | USA |
 |
AcelRx Pharmaceuticals
ACRX
|
40.3 M | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
38.9 M | - | 0.86 % | $ 117 M | USA |
 |
Cronos Group
CRON
|
154 M | $ 3.27 | - | $ 1.72 B | Canada |
 |
Agile Therapeutics
AGRX
|
30.5 M | - | 10.11 % | $ 58.2 M | USA |
 |
Aurora Cannabis
ACB
|
183 M | $ 5.4 | - | $ 86.3 M | Canada |
 |
Catalent
CTLT
|
512 M | - | - | $ 11.5 B | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
213 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
106 M | - | 2.45 % | $ 38.1 M | Canada |
 |
OrganiGram Holdings
OGI
|
41.4 M | $ 1.92 | - | $ 402 M | Canada |
 |
Organogenesis Holdings
ORGO
|
368 M | $ 4.82 | - | $ 635 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
113 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
763 M | - | - | $ 28.9 M |  Irlanda |
 |
Emergent BioSolutions
EBS
|
558 M | $ 11.41 | - | $ 584 M | USA |
 |
Pacira BioSciences
PCRX
|
279 M | $ 26.29 | - | $ 1.22 B | USA |
 |
Evoke Pharma
EVOK
|
12.6 M | $ 10.95 | - | $ 36.6 M | USA |
 |
Athenex
ATNX
|
96.7 M | - | -23.39 % | $ 1.76 M | USA |
 |
Rockwell Medical
RMTI
|
31.1 M | $ 0.92 | - | $ 21.5 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
196 M | $ 21.36 | - | $ 2.03 B |  France |
 |
Solid Biosciences
SLDB
|
130 M | $ 5.87 | - | $ 240 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
9.18 M | $ 3.59 | - | $ 4.46 M | USA |
 |
Evolus
EOLS
|
107 M | $ 7.04 | 1.88 % | $ 437 M | USA |
 |
Harrow Health
HROW
|
90.1 M | $ 47.06 | - | $ 1.53 B | USA |
 |
China Pharma Holdings
CPHI
|
2.6 M | $ 1.55 | -0.38 % | $ 27.1 M |  China |
 |
Veru
VERU
|
44 M | $ 2.42 | - | $ 326 M | USA |
 |
Bausch Health Companies
BHC
|
4.96 B | $ 6.92 | - | $ 2.53 B | Canada |
 |
Lannett Company
LCI
|
209 M | - | 1.15 % | $ 7.11 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
35.2 M | $ 2.53 | 1.61 % | $ 35.6 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
55.6 M | - | - | $ 193 M | Canada |
 |
PetIQ
PETQ
|
138 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
104 M | $ 4.06 | - | $ 122 M | USA |
 |
Jupiter Wellness
JUPW
|
39.6 M | - | - | $ 33.6 M | USA |
 |
Perrigo Company plc
PRGO
|
1.43 B | $ 13.14 | - | $ 1.81 B | USA |
 |
ProPhase Labs
PRPH
|
47.1 M | $ 0.11 | - | $ 1.74 M | USA |
 |
Radius Health
RDUS
|
304 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
22.5 M | - | -4.76 % | $ 65.3 M | USA |
 |
Sundial Growers
SNDL
|
102 K | $ 2.21 | - | $ 3.37 M | Canada |
 |
OptiNose
OPTN
|
129 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
44.2 M | - | -27.8 % | $ 2.56 M | USA |
 |
cbdMD
YCBD
|
28.9 M | $ 1.2 | - | $ 5.18 M | USA |
 |
SCYNEXIS
SCYX
|
67.5 M | $ 0.65 | - | $ 31.1 M | USA |
 |
Tricida
TCDA
|
153 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
1.52 B | $ 12.15 | - | $ 7.51 B | Canada |
 |
TherapeuticsMD
TXMD
|
9.82 M | $ 1.75 | - | $ 18.3 M | USA |
 |
Zomedica Corp.
ZOM
|
14.1 M | - | -0.21 % | $ 98 M | USA |
 |
Viatris
VTRS
|
4.88 B | $ 11.65 | - | $ 14.1 B | USA |